Hansoh Pharmaceutical Group Company Limited (3692) Stock Forecast & Price Target

Compare

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

3692 Analyst Ratings

Strong Buy

16 Buy

1 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Hansoh

Pharmaceutical Group Company Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

3692 Stock 12 Month Forecast

Average Price Target

HK$43.91

▲(27.05% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Hansoh Pharmaceutical Group Company Limited in the last 3 months. The average price target is HK$43.91 with a high forecast of HK$48.20 and a low forecast of HK$35.50. The average price target represents a 27.05% change from the last price of HK$34.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"HK$14","49":"HK$49","22.75":"HK$22.8","31.5":"HK$31.5","40.25":"HK$40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$48.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$43.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$35.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,22.75,31.5,40.25,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.06,36.99384615384616,37.92769230769231,38.861538461538466,39.79538461538462,40.729230769230774,41.66307692307693,42.596923076923076,43.53076923076923,44.464615384615385,45.39846153846154,46.332307692307694,47.26615384615385,{"y":48.2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.06,36.66384615384616,37.26769230769231,37.871538461538464,38.47538461538461,39.07923076923077,39.683076923076925,40.286923076923074,40.89076923076923,41.494615384615386,42.098461538461535,42.70230769230769,43.30615384615384,{"y":43.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.06,36.01692307692308,35.973846153846154,35.93076923076923,35.88769230769231,35.84461538461539,35.80153846153846,35.75846153846154,35.715384615384615,35.67230769230769,35.62923076923077,35.58615384615385,35.543076923076924,{"y":35.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.55,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.56,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.72,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.71,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$48.20

Average Price TargetHK$43.91

Lowest Price TargetHK$35.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bryce Generon

TR | OpenAI - 4o

HK$38

Hold

9.95%

Upside

Reiterated

10/23/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$43.23

Buy

25.09%

Upside

Reiterated

10/21/25

Huatai Securities Reaffirms Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$47

Buy

36.00%

Upside

Reiterated

10/20/25

Citic Securities Reaffirms Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692)

Jialin Zhang

Nomura

HK$35.47→HK$35.5

Hold

2.72%

Upside

Reiterated

10/18/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$43.23

Buy

25.09%

Upside

Reiterated

10/17/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$42

Buy

21.53%

Upside

Reiterated

10/17/25

Linda Shu

HSBC

HK$47

Buy

36.00%

Upside

Reiterated

09/30/25

Anita Wei

UBS

HK$48.2

Buy

39.47%

Upside

Reiterated

09/29/25

Hansoh Pharmaceutical Group Company Limited (3692) Receives a Buy from UBSUBS analyst Anita Wei reiterated a Buy rating and HK$48.20 price target on Hansoh Pharma (3692:HK) (OTC: HNSPF).

Yang Huang

J.P. Morgan

HK$43

Buy

24.42%

Upside

Initiated

09/25/25

Hansoh Pharmaceutical Group Company Limited (3692) Receives a New Rating from J.P. MorganJPMorgan analyst Yang Huang initiates coverage on Hansoh Pharma (3692:HK) (OTC: HNSPF) with a Overweight rating and a price target of HK$43.00.

Tony Ren

Macquarie

HK$40.5→HK$42.2

Buy

22.11%

Upside

Reiterated

09/08/25

Macquarie Sticks to Their Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$42.53

Buy

23.06%

Upside

Reiterated

09/07/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$44.32

Buy

28.24%

Upside

Reiterated

08/26/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$42.53

Buy

23.06%

Upside

Reiterated

08/20/25

Jill Wu

CMB International Securities

HK$45.26

Buy

30.96%

Upside

Reiterated

08/20/25

Michael Luo CFA

CLSA

HK$27.8→HK$43.1

Buy

24.71%

Upside

Reiterated

08/20/25

Hansoh Pharmaceutical Group Company Limited (3692) Receives a Buy from CLSACLSA analyst Michael Luo raised the price target on Hansoh Pharma (3692:HK) (OTC: HNSPF) to HK$43.10 (from HK$27.80) while maintaining a Outperform (2) rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bryce Generon

TR | OpenAI - 4o

HK$38

Hold

9.95%

Upside

Reiterated

10/23/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$43.23

Buy

25.09%

Upside

Reiterated

10/21/25

Huatai Securities Reaffirms Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$47

Buy

36.00%

Upside

Reiterated

10/20/25

Citic Securities Reaffirms Their Buy Rating on Hansoh Pharmaceutical Group Company Limited (3692)

Jialin Zhang

Nomura

HK$35.47→HK$35.5

Hold

2.72%

Upside

Reiterated

10/18/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$43.23

Buy

25.09%

Upside

Reiterated

10/17/25

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$42

Buy

21.53%

Upside

Reiterated

10/17/25

Linda Shu

HSBC

HK$47

Buy

36.00%

Upside

Reiterated

09/30/25

Anita Wei

UBS

HK$48.2

Buy

39.47%

Upside

Reiterated

09/29/25

Hansoh Pharmaceutical Group Company Limited (3692) Receives a Buy from UBSUBS analyst Anita Wei reiterated a Buy rating and HK$48.20 price target on Hansoh Pharma (3692:HK) (OTC: HNSPF).

Yang Huang

J.P. Morgan

HK$43

Buy

24.42%

Upside

Initiated

09/25/25

Tony Ren

Macquarie

HK$40.5→HK$42.2

Buy

22.11%

Upside

Reiterated

09/08/25

Macquarie Sticks to Their Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$42.53

Buy

23.06%

Upside

Reiterated

09/07/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$44.32

Buy

28.24%

Upside

Reiterated

08/26/25

Unknown Analyst

Huatai Securities

Not Ranked

Huatai Securities

HK$42.53

Buy

23.06%

Upside

Reiterated

08/20/25

Jill Wu

CMB International Securities

HK$45.26

Buy

30.96%

Upside

Reiterated

08/20/25

Michael Luo CFA

CLSA

HK$27.8→HK$43.1

Buy

24.71%

Upside

Reiterated

08/20/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hansoh Pharmaceutical Group Company Limited

1 Month

xxx

Success Rate

4/4 ratings generated profit

Average Return

+18.40%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +18.40% per trade.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+22.57%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.57% per trade.

1 Year

Jill WuCMB International Securities

Success Rate

3/3 ratings generated profit

Average Return

+100.00%

reiterated a buy rating 2 months ago

Copying Jill Wu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +100.00% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+150.63%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +150.63% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3692 Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 3692 has received 8 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 3692 average Analyst price target in the past 3 months is 43.91.

Each month's total comprises the sum of three months' worth of ratings.

3692 Financial Forecast

3692 Earnings Forecast

Next quarter’s earnings estimate for 3692 is HK$0.28 with a range of HK$0.25 to HK$0.32. The previous quarter’s EPS was HK$0.58. 3692 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 3692 has Outperformed its overall industry.

3692 Sales Forecast

Next quarter’s sales forecast for 3692 is HK$8.12B with a range of HK$8.12B to HK$8.12B. The previous quarter’s sales results were HK$7.98B. 3692 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 3692 has Outperformed its overall industry.

3692 Stock Forecast FAQ

What is HK:3692’s average 12-month price target, according to analysts?

Based on analyst ratings, Hansoh Pharmaceutical Group Company Limited’s 12-month average price target is 43.91.

What is HK:3692’s upside potential, based on the analysts’ average price target?

Hansoh Pharmaceutical Group Company Limited has 27.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hansoh Pharmaceutical Group Company Limited a Buy, Sell or Hold?

Hansoh Pharmaceutical Group Company Limited has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Hansoh Pharmaceutical Group Company Limited’s share price target?

The average share price target for Hansoh Pharmaceutical Group Company Limited is 43.91. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$48.20 ,and the lowest forecast is HK$35.50. The average share price target represents 27.05% Increase from the current price of HK$34.56.

What do analysts say about Hansoh Pharmaceutical Group Company Limited?

Hansoh Pharmaceutical Group Company Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Hansoh Pharmaceutical Group Company Limited?

To buy shares of HK:3692, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Hansoh Pharmaceutical Group Company Limited (3692) Stock Forecast & Price Target

3692 Analyst Ratings

3692 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hansoh Pharmaceutical Group Company Limited

3692 Analyst Recommendation Trends

3692 Financial Forecast

3692 Earnings Forecast

3692 Sales Forecast

3692 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts